LUCAID is an agentic AI system for precision lung cancer pathology that combines diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring to automated structured report generation.
Abstract
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.
Background: Conventional histopathological assessment of residual cancer burden (RCB) following neoadjuvant therapy for breast cancer relies on manual visual evaluation, lacking objective quantification of spatial interactions among tumor, necrosis, and lymphocyte compartments. This limits prognostic accuracy and imped...
Xin Shu, Fan Wang, Tian-Cheng Zhao et al.· Diagnostics· 0 citations
Artificial intelligence (AI) and radiomics have emerged as promising approaches in lung-cancer imaging by extracting quantitative features from routine medical images beyond visual assessment alone. Proof-of-concept studies span pulmonary nodule characterisation, molecular biomarker prediction, treatment-response asses...
J. Naidu, V. Baskaradoss· Academia Medical Imaging and...· 0 citations
Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrai...
Shuai-Yu Zheng, Chi Lv, Zhen Yao· Frontiers in Medicine· 0 citations
PURPOSE
Pretreatment estimation of pathological complete response (pCR) to neoadjuvant chemotherapy may support risk stratification and future response-adapted clinical studies in breast cancer. However, existing deep learning approaches often rely on "black-box" visual pattern recognition, suffering from poor interpre...
Current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology are examined and their potential to be incorporated into a proposed multimodal model is examined.
T. Chakrabarti, A. Mansour, Xi-Wei Wu et al.· Cancers· 0 citations
This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints, and separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation.
Liu-Yang Yang, Liyu Shan, Xiang-Mei Yao et al.· JMIR Cancer· 0 citations
Machine-learning networks can learn without detailed instructions from a designer. Those that do may offer insight into how the brain reorganizes itself during learning.
Exploring how generative AI could make machine vision more accessible to businesses. The post GenEye in a Box: Making Machine Vision Something You Can Just Ask For appeared first on GPT-Lab.
MIT News · Artificial Intelligence· news.mit.eduSep 29, 2026
Professor Sherry Turkle’s new book, “Artificial Intimacy,” offers a withering critique of chatbots and the antisocial dynamics she believes they encourage.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.